Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05159180
Other study ID # IIBSP-IMS-2021-74
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 13, 2021
Est. completion date December 31, 2022

Study information

Verified date December 2021
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact Jose M Guerra, MD, PhD
Phone +34935537058
Email jguerra@santpau.cat
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Precise identification of the atrial fibrosis is essential for successful catheter ablation of atrial arrhythmias in patients with atrial fibrillation. Voltage mapping of endocardial electrograms is currently used to delineate the anatomical substrate, but this is influenced by the direction of the activation wave front and is limited by the patient-specific thresholds. Mapping of local myocardial electrical impedance may overcome these limitations.


Description:

Clinical series: Patients with atrial arrythmias undergoing catheter ablation of these will be submitted to mapping of both voltage and tissue impedance. Likewise, the accuracy of the two maps identifying the extent of the substrate will be assesssed by gadolinium imaging. The impedance system is already constructed and certified for clinical research use.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date December 31, 2022
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Age between 18 and 85 years. - That they understand and sign the informed consent. - That they do not present any contraindication.- Pass the exploration and tests prior to bioimpedance measurements. Exclusion Criteria: - Age outside the range described in the inclusion criteria. - Subjects who present any type of complication during the procedure. - Pregnancy.

Study Design


Intervention

Device:
cardioz mapping
Patients will be submitted to mapping of both voltage and tissue impedance.

Locations

Country Name City State
Spain Hospital de la Santa Creu i Sant Pau Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Amorós-Figueras G, Jorge E, Alonso-Martin C, Traver D, Ballesta M, Bragós R, Rosell-Ferrer J, Cinca J. Endocardial infarct scar recognition by myocardial electrical impedance is not influenced by changes in cardiac activation sequence. Heart Rhythm. 2018 — View Citation

Amorós-Figueras G, Jorge E, García-Sánchez T, Bragós R, Rosell-Ferrer J, Cinca J. Recognition of Fibrotic Infarct Density by the Pattern of Local Systolic-Diastolic Myocardial Electrical Impedance. Front Physiol. 2016 Aug 31;7:389. doi: 10.3389/fphys.2016 — View Citation

Jorge E, Amorós-Figueras G, García-Sánchez T, Bragós R, Rosell-Ferrer J, Cinca J. Early detection of acute transmural myocardial ischemia by the phasic systolic-diastolic changes of local tissue electrical impedance. Am J Physiol Heart Circ Physiol. 2016 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Comparative detection of atrial scar by voltage mapping Voltage will be measured at different sites of the atrial scar and healthy tissue. 30 minutes
Primary Comparative detection of atrial scar by impedance mapping Myocardial local impedance spectroscopy will be measured at different sites of the atrial scar and healthy tissue. 30 minutes
Primary Comparative detection of atrial scar by gadolinium enhanced MR imaging Intensity of gadolinium will be measured at different sites of the infarct scar and healthy tissue 30 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT02245009 - Safety of External Electrocardioversion in Device Patients N/A
Completed NCT02241382 - Cologne Cardioversion Study N/A
Completed NCT01439386 - Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter Phase 3
Not yet recruiting NCT06293430 - Registry on Luma Vision's VERAFEYE System (ENLIgHT)
Recruiting NCT03209583 - ATrial Tachycardia PAcing Therapy in Congenital Heart
Recruiting NCT06083012 - Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation
Recruiting NCT05883631 - RESOLVE-AF: Clinical Evaluation of the Ablacathâ„¢ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. N/A
Recruiting NCT05434650 - Abbott Atrial Fibrillation Post Approval Study
Recruiting NCT05014802 - Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Completed NCT05113056 - AcQForce Pulsed Field Ablation-CE N/A
Completed NCT05362656 - AutoMatic disPERsion Tagging Function Preliminary Evaluation N/A
Recruiting NCT05411614 - Hybrid AbLaTion of Atrial Fibrillation N/A
Active, not recruiting NCT05213104 - Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia Phase 3
Active, not recruiting NCT03053843 - Mediterranean Diet Plus Extravirgin Olive Oil in the Prevention of Recurrent Arrhythmias. The PREDIMAR (PREvención Con DIeta Mediterránea de Arritmias Recurrentes) Trial N/A
Completed NCT01188356 - EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients
Recruiting NCT03458273 - Real Zero Fluoroscopy Catheter Ablation.
Completed NCT04394923 - Relationship Between the Posterior Atrial Wall and the Esophagus: Esophageal Position and Temperature MEasurement During Atrial Fibrillation Ablation. N/A
Completed NCT02106663 - Effectiveness Study of Circumferential vs. Segmental Ablation in Paroxysmal Atrial Fibrillation N/A
Completed NCT03854149 - Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
Recruiting NCT05488470 - QT Changes as Detected From LINQ ECG During and After Antiarrhythmic Loading (LINQ QT)